Overview

A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)

Status:
Completed

Trial end date:
2011-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the pharmacokinetics, pharmacodynamics, and the safety of rabeprazole sodium for the treatment of gastroesophageal reflux disease (GERD) in newborns and pre-term infants.

Phase:

Phase 1

Details

Lead Sponsor:

Janssen Research & Development, LLC

Collaborator:

Eisai Inc.

Treatments:

Rabeprazole